Visceral obesity augments prescription use: An analysis of the cross-sectional study of NHANES 2011-2018.

ABSTRACT:

Background

Visceral obesity (VATob) increases the risk for many diseases. Central obesity has been associated with an augmented prescription use; however, there is a paucity of research focused on VATob. Here, the aim was to evaluate the association between VATob and prescription use.

Methods

Data was collected from the NHANES dataset (2011-2018). Visceral adipose tissue was measured using dual x-ray absorptiometry, and VATob was defined as ≥100 cm2. Prescription use was collected from the RXQ_RX files and classified according to Vademecum. Association between VATob and prescription use was determined with logistic regression and reported as odds ratios (ORs) with 95% confidence intervals (95%CIs).

Results

10,952 participants (weighted: 121,090,702) were included, in

SUBMITTER: Acevedo-Fernandez M 

PROVIDER: S-EPMC11790123 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature